Artelo Biosciences Inc. (NASDAQ:ARTL) has announced the filing of a method of use patent with the USPTO covering Fatty Acid Binding Protein 5 inhibitors’ use in treating psychological disorders. Some of the psychological disorders covered include post-traumatic stress disorder and anxiety, representing a considerable economic and healthcare burden globally.
Artelo announces positive preclinical FABP5 Inhibitor results
The company has also announced encouraging preclinical results in animal models showing the inhibition of FABP5. The inhibition results in increased anandamide in the brain areas responsible for psychological disorders such as PTSD and anxiety-related symptoms. The FABP5 inhibitor microinfusions into the medial prefrontal cortex of rodents and testing them for PTSD and anxiety-related traumatic memory processing through fear conditioning showed strong regulation of the FABP5 inhibitor’s disorders.
It is currently interventional therapeutic approaches employed in treating anxiety disorders like chronic stress and PTSD. Also, medications that affect norepinephrine and/or serotonin can also be used. Unfortunately, the most prescribed anti-anxiety treatments are associated with side effects that include cognitive impairments, drug dependence and withdrawal, and metabolic symptoms. According to the new data, FABP5 inhibition could offer a proprietary treatment approach for certain psychological disorders that have less deleterious impact compared to current methodologies.
FABP5 Inhibitor platform can treat psychological disorders
Gregory Gorgas, the CEO and President of Artelo, said that the patent filing shows the significant expansion of its patent estate initiatives. This will add a potential treatment for psychological disorders such as anxiety and PTSD using its FABP5 inhibitor platform, ART26.12. Gorgas added that animal models have demonstrated that FABP5’s inhibition holds significant potential in treating psychological conditions with any adverse effects related to current treatments. Interestingly, there is a possibility that COVID-19 survivors could develop PTSD. Others face anxiety and stress due to the pandemic, which highlights the need for an effective and safe treatment alternative.
Recently the company announced the expansion of its current global commercial license agreement with The Research Foundation for The State University of New York, Stony Brook.